Stock AnalizInnoviva, Inc. INVA
Biotechnology: Pharmaceutical Preparations · IPO 2004 · data as of November 13, 2026
Innoviva, Inc. (INVA) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $438M and net income of $193M, a net margin of 44.1%.
Its overall Stock Analiz score is 3.8 out of 5 (good). The strongest part is value (5/5); the weakest is shareholder returns (2/5).
Key numbers: a P/E of 8.1, a price to free cash flow of 7.4, 5-year revenue growth of 4% a year, a 5-year average ROIC of 17%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 177% above the current price.
Score: 3.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $438M | $411M | $359M | $310M | $331M | $392M | $337M | $261M | $261M | $217M | $134M |
| Net income | $193M | $271M | $23M | $180M | $214M | $266M | $224M | $157M | $395M | $134M | $60M |
| Free cash flow | $183M | $196M | $188M | $141M | $202M | $364M | $313M | $257M | $224M | $142M | $61M |
| EPS (diluted) | $2.00 | $3.30 | $0.36 | $2.20 | $2.37 | $2.87 | $2.02 | $1.43 | $3.53 | $1.17 | $0.53 |
| Net margin | 44.1% | 65.9% | 6.5% | 57.9% | 64.6% | 67.8% | 66.6% | 60.3% | 151.4% | 61.8% | 44.6% |
| ROIC | — | 9.4% | 9.1% | 9.4% | 19.9% | 38.4% | 27.4% | 27.1% | 31.3% | 42.3% | 29.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $34.80, 83% above the current price; targets range from $18.00 to $46.00; the consensus rating is “Buy”; expected EPS is $0.85 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Innoviva’s P/E ratio?
About 8.1, based on the last twelve months of diluted earnings per share (forward P/E about 9.5).
Is Innoviva stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 177% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Innoviva pay a dividend?
Not currently.
Is Innoviva a good stock to buy?
We do not give buy or sell advice. Innoviva scores 3.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.